← Leaderboards
William Y Kim
Dana-Farber Cancer Institute
$15,134,536
Attributed
$20,406,965
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,406,965 · 10
By mechanism
R01$10,821,878 · 7
K12$5,353,810 · 1
T32$3,553,640 · 1
K08$677,637 · 1
Top collaborators
- Benjamin G Vincent7 shared
- Jen Jen Yeh7 shared
- Zibo Li4 shared
- Jin Xie4 shared
- Daniel Issac Dominguez2 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- William G Kaelin$28,163,102
- Othon Iliopoulos$11,620,320
- Zoltan P Arany$25,367,590
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorCellsResistanceIn VivoResponseMouse ModelIn VitroCessation Of LifePathway InteractionsDoseMalignant Neoplasm Of Urinary BladderUnited StatesSignal TransductionMutationBladder NeoplasmVascular Endothelial Growth FactorsPlayMuscleFda ApprovedFibroblastsCancer Cell LineBaseAffect
Grant awards (45)
UNC Oncology K12$810,000
K12 · FY2025 · CA · contact PI
Triggering Aberrant RNA Processing for RCC Therapy$618,056
R01 · FY2025 · CA · contact PI
Targeting APOBEC3-induced squamous differentiation in bladder cancer$514,582
R01 · FY2025 · CA · contact PI
UNC Integrated Translational Oncology Program (UNC-iTOP)$440,302
T32 · FY2025 · CA
UNC Oncology K12$756,019
K12 · FY2024 · CA · contact PI
Triggering Aberrant RNA Processing for RCC Therapy$618,057
R01 · FY2024 · CA · contact PI
UNC Integrated Translational Oncology Program (UNC-iTOP)$567,329
T32 · FY2024 · CA
Chemotherapy and the Bladder Cancer Immune Microenvironment$537,831
R01 · FY2024 · CA · contact PI
Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer$503,511
R01 · FY2024 · CA
Chemotherapy and the Bladder Cancer Immune Microenvironment$82,863
R01 · FY2024 · CA · contact PI
UNC Integrated Translational Oncology Program (UNC-iTOP)$569,539
T32 · FY2023 · CA
Chemotherapy and the Bladder Cancer Immune Microenvironment$554,816
R01 · FY2023 · CA · contact PI
Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer$525,898
R01 · FY2023 · CA
In vivo Assessment of Chemotherapy Remodeling of the Bladder Cancer Immune Microenvironment$74,967
R01 · FY2023 · CA · contact PI
UNC Oncology Clinical/Translational Research Training Program (OCT-RTP)$595,127
K12 · FY2022 · CA · contact PI
Chemotherapy and the Bladder Cancer Immune Microenvironment$554,812
R01 · FY2022 · CA · contact PI
UNC Integrated Translational Oncology Program (UNC-iTOP)$541,135
T32 · FY2022 · CA
Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer$531,155
R01 · FY2022 · CA
UNC Oncology Clinical/Translational Research Training Program (OCT-RTP)$718,905
K12 · FY2021 · CA · contact PI
UNC Integrated Translational Oncology Program (UNC-iTOP)$572,494
T32 · FY2021 · CA
Chemotherapy and the Bladder Cancer Immune Microenvironment$566,138
R01 · FY2021 · CA · contact PI
Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer$552,591
R01 · FY2021 · CA
UNC Oncology Clinical/Translational Research Training Program (OCT-RTP)$712,771
K12 · FY2020 · CA · contact PI
UNC Integrated Translational Oncology Program (UNC-iTOP)$579,408
T32 · FY2020 · CA
Chemotherapy and the Bladder Cancer Immune Microenvironment$566,138
R01 · FY2020 · CA · contact PI
Kinase Inhibition in Kidney Cancer$432,423
R01 · FY2020 · CA · contact PI
UNC Oncology Clinical/Translational Research Training Program (OCT-RTP)$719,220
K12 · FY2019 · CA · contact PI
Kinase Inhibition in Kidney Cancer$419,450
R01 · FY2019 · CA · contact PI
UNC Integrated Translational Oncology Program (UNC-iTOP)$283,433
T32 · FY2019 · CA
UNC Oncology Clinical/Translational Research Training Program (OCT-RTP)$547,714
K12 · FY2018 · CA · contact PI
Kinase Inhibition in Kidney Cancer$432,423
R01 · FY2018 · CA · contact PI
Kinase Inhibition in Kidney Cancer$432,423
R01 · FY2017 · CA · contact PI
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling$405,890
R01 · FY2017 · CA · contact PI
UNC Oncology Clinical Translational Research Training Program$494,054
K12 · FY2016 · CA · contact PI
Kinase Inhibition in Kidney Cancer$432,423
R01 · FY2016 · CA · contact PI
Characterization and therapeutic targeting of HIF in LKB1 - deficient lung cancer$287,693
R01 · FY2014 · CA · contact PI
Characterization and therapeutic targeting of HIF in LKB1 - deficient lung cancer$278,795
R01 · FY2013 · CA · contact PI
Characterization and therapeutic targeting of HIF in LKB1 - deficient lung cancer$296,590
R01 · FY2012 · CA · contact PI
Characterization and therapeutic targeting of HIF in LKB1 - deficient lung cancer$296,590
R01 · FY2011 · CA · contact PI
Characterization and therapeutic targeting of HIF in LKB1 - deficient lung cancer$305,763
R01 · FY2010 · CA · contact PI
Imaging VHL-Associated Tumors with Labile O2 Biosensors$135,574
K08 · FY2008 · CA · contact PI
Imaging VHL-Associated Tumors with Labile O2 Biosensors$135,574
K08 · FY2007 · CA · contact PI
Imaging VHL-Associated Tumors with Labile O2 Biosensors$135,574
K08 · FY2006 · CA · contact PI
Imaging VHL-Associated Tumors with Labile O2 Biosensors$135,574
K08 · FY2005 · CA
Imaging VHL-Associated Tumors with Labile O2 Biosensors$135,341
K08 · FY2004 · CA